Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Chemical Society
2019-04-01
|
| Series: | ACS Omega |
| Online Access: | http://dx.doi.org/10.1021/acsomega.9b00199 |
| id |
doaj-2f7bcabc827d4448a44a96c74939a085 |
|---|---|
| record_format |
Article |
| spelling |
doaj-2f7bcabc827d4448a44a96c74939a0852020-11-25T03:04:10ZengAmerican Chemical SocietyACS Omega2470-13432019-04-01446703670810.1021/acsomega.9b00199Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2Scott D. Bembenek0Hariharan Venkatesan1Hillary M. Peltier2Mark D. Rosen3Terrance D. Barrett4Kimon C. Kanelakis5Heather L. Palomino6Theresa I. Brondstetter7Taraneh Mirzadegan8Michael H. Rabinowitz9†Discovery Sciences, Janssen Research & Development, San Diego, California, United States†Discovery Sciences, Janssen Research & Development, San Diego, California, United StatesJanssen Research & Development, San Diego, California, United StatesJanssen Research & Development, San Diego, California, United States§Cardiovascular Metabolic Therapeutic Area, Janssen Research & Development, San Diego, California, United StatesJanssen Research & Development, San Diego, California, United StatesJanssen Research & Development, San Diego, California, United StatesJanssen Research & Development, San Diego, California, United States†Discovery Sciences, Janssen Research & Development, San Diego, California, United StatesJanssen Research & Development, San Diego, California, United Stateshttp://dx.doi.org/10.1021/acsomega.9b00199 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Scott D. Bembenek Hariharan Venkatesan Hillary M. Peltier Mark D. Rosen Terrance D. Barrett Kimon C. Kanelakis Heather L. Palomino Theresa I. Brondstetter Taraneh Mirzadegan Michael H. Rabinowitz |
| spellingShingle |
Scott D. Bembenek Hariharan Venkatesan Hillary M. Peltier Mark D. Rosen Terrance D. Barrett Kimon C. Kanelakis Heather L. Palomino Theresa I. Brondstetter Taraneh Mirzadegan Michael H. Rabinowitz Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2 ACS Omega |
| author_facet |
Scott D. Bembenek Hariharan Venkatesan Hillary M. Peltier Mark D. Rosen Terrance D. Barrett Kimon C. Kanelakis Heather L. Palomino Theresa I. Brondstetter Taraneh Mirzadegan Michael H. Rabinowitz |
| author_sort |
Scott D. Bembenek |
| title |
Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2 |
| title_short |
Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2 |
| title_full |
Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2 |
| title_fullStr |
Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2 |
| title_full_unstemmed |
Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2 |
| title_sort |
beyond traditional structure-based drug design: the role of iron complexation, strain, and water in the binding of inhibitors for hypoxia-inducible factor prolyl hydroxylase 2 |
| publisher |
American Chemical Society |
| series |
ACS Omega |
| issn |
2470-1343 |
| publishDate |
2019-04-01 |
| url |
http://dx.doi.org/10.1021/acsomega.9b00199 |
| work_keys_str_mv |
AT scottdbembenek beyondtraditionalstructurebaseddrugdesigntheroleofironcomplexationstrainandwaterinthebindingofinhibitorsforhypoxiainduciblefactorprolylhydroxylase2 AT hariharanvenkatesan beyondtraditionalstructurebaseddrugdesigntheroleofironcomplexationstrainandwaterinthebindingofinhibitorsforhypoxiainduciblefactorprolylhydroxylase2 AT hillarympeltier beyondtraditionalstructurebaseddrugdesigntheroleofironcomplexationstrainandwaterinthebindingofinhibitorsforhypoxiainduciblefactorprolylhydroxylase2 AT markdrosen beyondtraditionalstructurebaseddrugdesigntheroleofironcomplexationstrainandwaterinthebindingofinhibitorsforhypoxiainduciblefactorprolylhydroxylase2 AT terrancedbarrett beyondtraditionalstructurebaseddrugdesigntheroleofironcomplexationstrainandwaterinthebindingofinhibitorsforhypoxiainduciblefactorprolylhydroxylase2 AT kimonckanelakis beyondtraditionalstructurebaseddrugdesigntheroleofironcomplexationstrainandwaterinthebindingofinhibitorsforhypoxiainduciblefactorprolylhydroxylase2 AT heatherlpalomino beyondtraditionalstructurebaseddrugdesigntheroleofironcomplexationstrainandwaterinthebindingofinhibitorsforhypoxiainduciblefactorprolylhydroxylase2 AT theresaibrondstetter beyondtraditionalstructurebaseddrugdesigntheroleofironcomplexationstrainandwaterinthebindingofinhibitorsforhypoxiainduciblefactorprolylhydroxylase2 AT taranehmirzadegan beyondtraditionalstructurebaseddrugdesigntheroleofironcomplexationstrainandwaterinthebindingofinhibitorsforhypoxiainduciblefactorprolylhydroxylase2 AT michaelhrabinowitz beyondtraditionalstructurebaseddrugdesigntheroleofironcomplexationstrainandwaterinthebindingofinhibitorsforhypoxiainduciblefactorprolylhydroxylase2 |
| _version_ |
1724682540171657216 |